We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Emily J. Orban
Emily J. Orban
Products
PRODUCTS
Michigan Medicine
Emily J. Orban
Price:
$117.00
View
DDP Specialty Electronic Materials
Emily J. Orban
Price:
$117.00
View
Ionetix Corp.
Emily J. Orban
Price:
$117.00
View
Sanofi S.P.A.
Emily J. Orban
Price:
$117.00
View
Lannett Company, Inc.
Emilie Kahn
and
Emily J. Orban
Price:
$117.00
View
Accrapac dba KIK Custom Products, Inc.
Bei Y. He
and
Emily J. Orban
Price:
$117.00
View
Pharmakon Compounding Pharmacy, Inc.
Robert M. Barbosa
,
Bei Y. He
, and
Emily J. Orban
Price:
$117.00
View
Pharmakon Pharmaceuticals, Inc.
Emilie Kahn
,
Lisa T. Michel
,
Emily J. Orban
, and
Gary C. Pecic
Price:
$117.00
View
Clark Professional Pharmacy, LLC
Emily J. Orban
and
Abuzar Shamim
Price:
$117.00
View
Pharmakon Pharmaceuticals, Inc.
Sarah M. Napier
and
Emily J. Orban
Price:
$117.00
View
View All Products by Emily J. Orban
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
FDA, FTC and DOJ Enforcement of Medical Device Regulations
Using Real-World Evidence in Drug and Device Submissions
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More